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A B S T R A C T
Background: Human atrial natriuretic peptide (hANP) and spontaneous nitric oxide (NO) donor share
cyclic guanosine monophosphate (cGMP) as a second messenger, but their effect on myocardium may
differ. We compared the effect of hANP and sodium nitroprusside (SNP) on left ventricular (LV)
mechano-energetics in heart failure (HF).
Methods: Ten patients with HF due to previous myocardial infarction (LV ejection fraction: 45  3%) were
instrumented with conductance and coronary sinus thermodilution catheters. LV contractility (Ees: slope of
end-systolic pressure–volume relation) and the ratio of LV stroke work (SW) to myocardial oxygen
consumption (SW/MVO2 = mechanical efﬁciency) were measured in response to intravenous infusion of ANP
(0.05 mg/kg/min) or SNP (0.3 mg/kg/min) to lower blood pressure by at least 10 mmHg, and changes in
plasma cGMP.
Results: SNP had no effect on Ees, SW, or MVO2, thus SW/MVO2 remained unchanged (40.54  5.84% to
36.59  5.72%, p = 0.25). ANP increased Ees, and decreased MVO2 with preserved SW, resulting in improved
SW/MVO2 (40.49  6.35% to 50.30  7.96%, p = 0.0073). Infusion of ANP (10.42–34.95 pmol/ml, p = 0.0003)
increased cGMP levels, whereas infusion of SNP had no effect (10.42–12.23 pmol/ml, p = 0.75).
Conclusions: Compared to SNP, the ANP-dependent increase in cGMP may ameliorate myocardial
inotropy and energetics in HF.
 2015 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.
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Congestive heart failure (CHF) is a complex syndrome that
results from various underlying conditions, including acute and
chronic ischemic heart disease, cardiomyopathies, myocarditis,
and pressure overload, that lead to an inability to pump blood at an
output sufﬁcient to meet the requirements of tissues in the body.
Current therapies for CHF include loop diuretics to reduce
intravascular volume, vasodilators to reduce vascular resistance,
and inotropic agents to increase myocardial contractility.* Corresponding author at: Kobe University Graduate School of Medicine,
Division of Cardiovascular Medicine, Department of Internal Medicine, 7-5-1
Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan. Tel.: +81 78 382 5846;
fax: +81 78 382 5859.
E-mail address: shinke@med.kobe-u.ac.jp (T. Shinke).
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0914-5087/ 2015 Published by Elsevier Ltd on behalf of Japanese College of CardioloVasodilatation using a nitric oxide (NO) donor such as
nitroglycerin and sodium nitroprusside (SNP) is a widely used
therapeutic strategy for CHF. NO has vasodilatation effects in
vascular smooth muscle cells via the activation of soluble
guanylate cyclase and an increase in intracellular levels of
guanosine 30,50-cyclic monophosphate (cGMP), an intracellular
messenger. In addition to vasodilatation, several experimental
studies have suggested that NO donors affect cardiac contractility.
De Mulder et al. demonstrated that SNP enhances the left
ventricular (LV) contractile response to b-adrenergic stimulation
[1]. In contrast, Shinke et al. demonstrated that inhibition of
endogenous NO synthase enhances the LV contractile response to
b-adrenergic stimulation [2]. The precise effects of NO on cardiac
function and mechano-energetics in patients with CHF, however,
have not been investigated clinically.gy.
Fig. 1. LV pressure–volume relation. LV pressure–volume relation assessed by
manometer-tipped LV conductance catheter. LV, left ventricular; Ees, slope of the LV
end-systolic pressure–volume relation; SW, stroke work (J) calculated as the area
bound by the pressure–volume trajectory of 1 beat; ESPVR, end-systolic pressure–
volume relation.
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responses via binding the particulate guanylate cyclase-coupled
receptor, that is, the natriuretic peptide receptor-A (NPR-A) [3],
and this natriuretic peptide utilizes cGMP as a second messenger
similarly to NO. In addition to its potent natriuretic and
vasodilatory properties, ANP has various other beneﬁcial effects,
such as anti-inﬂammatory effects, suppression of sympathetic
tone and catecholamine production, and inhibition of the renin–
angiotensin system [4–6].
The effect of ANP on myocardial contractility, however, is
controversial. Ohte et al. reported that ANP had a negative
inotropic effect in both normal dogs and dogs with CHF [7]. On the
other hand, Lainchbury et al. demonstrated that ANP had a positive
inotropic effect in normal dogs, and no inotropic effect in dogs with
CHF [8]. Mizuno et al. demonstrated that ANP administration
increased Ees, an index of contractility, in patients with CHF [9].
Given these various potent biologic activities, clariﬁcation of
the effects of ANP on contractility and cardiac mechano-energetics
is important toward establishing a therapeutic strategy for CHF. In
the present study, we examined the effects of an NO donor and ANP
on cardiac performance and mechano-energetics in patients with
LV dysfunction.
Methods
Patient population
Studies were performed in 10 patients (mean age
68.1  9.5 years, men/women = 5/5) with prior myocardial infarction
(MI). They underwent diagnostic cardiac catheterization for evalua-
tion of heart function at least 1 month after the onset of MI.
All patients received percutaneous coronary stenting within
48 h of the onset of symptoms and had no residual epicardial
coronary stenosis, dyskinetic LV wall motion, or more than
moderate mitral valve regurgitation at the time of this study
protocol. All patients were in sinus rhythm and were diagnosed
with New York Heart Association functional class II CHF. Before
cardiac catheterization, angiotensin-converting enzyme inhibitors
and b-blockers were withheld for at least for 24 h and more than
72 h, respectively. Written informed consent was obtained from all
patients, and the study protocol was approved by the Institutional
Committee on Human Research at Kobe University Hospital.
Cardiac catheterization procedure
Patients had undergone routine right and left heart catheteri-
zation, left ventriculography, and coronary arteriography under
fasting conditions without medication. A 6F conductance catheter
(CardioDynamics, Rijnsberg, The Netherlands) was advanced into
the LV through the right radial artery, and a 2F Millar Instruments
catheter (Millar Instruments, Houston, TX, USA) was advanced into
the LV through the lumen of the conductance catheter. An 8F
coronary thermodilution catheter (Cordis Webster, Inc., Diamond
Bar, CA, USA) was then advanced into the coronary sinus through
the right jugular vein. The conductance catheter was attached to
a stimulator/processor (Leycom Sigma-5, CardioDynamics). The
electrocardiogram and hemodynamic parameters were recorded
on a strip-chart recorder. Each measurement of the hemodynamic
parameters was obtained as the mean value of 8–10 consecutive
sinus beats.
Assessment of LV cardiac mechano-energetics
Coronary sinus blood ﬂow (CSF) was measured with the
previously described thermodilution technique [10]. Coronary
blood was sampled from the distal lumen of the coronarythermodilution catheter for oximetry and determination of
myocardial oxygen consumption (MVO2). MVO2 per minute was
calculated as the product of CSF (ml/min) and the arterial-coronary
sinus oxygen content difference (vol%) divided by heart rate to
yield MVO2 per beat (ml O2/beat).
As previously described [11,12], pressure–volume loops for the
sequence beats during the transient reduction in the preload by the
Valsalva maneuver were recorded over 8–10 beats, and several
pressure–volume loops were obtained from one subject. LV
contractility is expressed as Ees, which is the slope of the linear
end-systolic pressure–volume relation (ESPVR), as shown in Fig. 1
[13]. Ees is applied to the LV of the intact animal and humans as a
load-independent index of myocardial contractility [14].
Effective arterial elastance (Ea) is a variable that incorporates
the values of Windkessel model elements and heart rate as the
ratio of end-systolic pressure to stroke volume, and corresponds to
the slope of the line connecting the end-systolic pressure–volume
point and the end-diastolic point on the volume axis [15]. The ratio
of effective Ea to ventricular elastance (Ea/Ees) represents
ventriculoarterial coupling. We normalized Ees and Ea (mmHg/
ml/m2) to the body surface area to permit comparison among
patients in the present study, as described previously [13].
The rate of LV relaxation was analyzed using Tau. Tau is the time
constant of LV pressure decay during isovolumic relaxation,
quantiﬁed from a plot of dP/dt vs P (P = P0et/T + Pb), where P is
LV pressure, t is the time from peak dP/dt, T is the time constant of
isovolumic pressure decay, and P0 and Pb are constants determined
by the data [2,16].
Stroke work (SW) was calculated as the area bound by the
pressure–volume trajectory of 1 beat. Systolic pressure–volume
area (PVA) was calculated as the area bound by the ESPVR, end-
diastolic pressure–volume relation (EDPVR), and the systolic
pressure–volume trajectory of 1 beat. Mechanical efﬁciency was
calculated as the ratio of SW (J/beat) to MVO2 per beat (J/beat),
where 1 mmHg/ml SW and 1 ml O2 of oxygen consumption
correspond to 1.33  104 and 20 J, respectively [17].
Table 1
Baseline characteristics of the study population.
EF (%) 45.1  3.1
MAP (mmHg) 93.6  6.0
LVSP (mmHg) 131.8  9.5
LVEDP (mmHg) 16.3  2.5
RA (mmHg) 8.0  0.6
PCWP (mmHg) 12.7  2.2
CI (l/min/m2) 2.7  0.2
Peak +dP/dt (mmHg/s) 1904  93
Tau (ms) 48.1  2.6
Peak dP/dt (mmHg/s) 2209  398
EF, left ventricular ejection fraction; MAP, mean arterial pressure; LVSP, left
ventricular systolic pressure; LVEDP, left ventricular end-diastolic pressure; RA,
mean right atrial pressure; PCWP, mean pulmonary artery wedge pressure; CI,
cardiac output/body index; Peak +dP/dt, peak positive dP/dt; Tau, time constant
of LV pressure decay during isovolumic relaxation; Peak dP/dt, peak negative
dP/dt.
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Control study
After routine right and left heart catheterization, atrial pacing
was started at 90 bpm or at 15 bpm above the baseline heart rate.
Atrial pacing was continued for the duration of the study. At least
20 min after catheterization for stabilization of hemodynamics, the
pressure–volume loops and CSF were measured, and blood gas
samples were extracted from the coronary sinus and LV. Plasma
cGMP levels were measured from the coronary sinus. ESPVR was
obtained during the Valsalva maneuver.
Sodium nitroprusside and atrial natriuretic peptide study
After completion of the control study, SNP in 5% glucose was
intravenously administered via the sheath lumen of the right jugular
vein for 15 min. After steady hemodynamic and contractile states
were achieved, the effects of SNP on cardiac mechano-energetics
were evaluated as in the control study. Sufﬁcient data were
obtained, including the pressure volume curve, CSF, and ESPVR.
After evaluating the effects of SNP, the SNP infusion was
discontinued and hemodynamic variables were monitored for at
least 20 min until they returned to control values. After
conﬁrmation that the effect of SNP had vanished completely
and hemodynamic variables returned to control steady states, the
same measurements were repeated as a re-control study. The
effects of ANP on cardiac mechano-energetics were then evaluated
in the same way. In the ANP study, genetic recombinant a-human
atrial natriuretic peptide (hANP) in 5% glucose was administered
for 0.05 mg/kg/min via the same route as SNP infusion for 15 min.
After stabilization of hemodynamic variables was conﬁrmed, the
same measurements were repeated.
On the basis of our preliminary study, the SNP and hANP doses
were set at 0.3 mg/kg/min and 0.05 mg/kg/min, respectively,
because we conﬁrmed that the systemic blood pressure depressant
effects by these two drugs were almost equivalent, and these
concentrations were within clinically therapeutic doses. In 5 of the
10 patients enrolled in this study, the order of the administration of
SNP and hANP was reversed to control for the effects of the
administration order of the drug.
Statistical analysis
Data are shown as mean  SEM. ESPVR values were obtained
through linear regression analysis. The effects of SNP and ANP were
analyzed independently with a paired t test with Bonferroni’s
correction for multiple comparisons. Drug-induced changes were
analyzed with two-way repeated measures analysis of variance. A
p-value less than 0.05 was considered signiﬁcant.Table 2
Inﬂuence of SNP and ANP on hemodynamic variables.
Control (before SNP) S
LVSP (mmHg) 131.8  9.5 111.6
LVEDP (mmHg) 16.3  2.5 13.0
Peak +dP/dt (mmHg/s) 1904  93 1832
CSF (ml/min) 88.4  16.7 83.6
O2 cont diff (vol%) 63.5  2.0 62.1
MVO2 (J/min) 173.6  25.9 162.8
Peak dP/dt (mmHg/s) 2209  398 1443
Tau (ms) 48.1  2.6 44.8
SNP, sodium nitroprusside; ANP, atrial natriuretic peptide; LVSP, left ventricular sys
positive dP/dt; CSF, coronary sinus blood ﬂow; O2 cont diff, coronary arteriovenous oxyg
negative dP/dt; Tau, time constant of LV pressure decay during isovolumic relaxation
Values are expressed as mean  SEM.
* p < 0.05 vs control.
** p < 0.05 vs control 2.Results
Patient characteristics
Baseline characteristics of the study subjects are shown in
Table 1. None of the study subjects developed signiﬁcant
narrowing of the main coronary arteries. None of the patients
had signiﬁcant mitral regurgitation or a trans-aortic valve
pressure gradient. Ejection fractions, +dP/dt, dP/dt, and Tau
were 45.1  3.1, 1904  93, 2209  298, and 48.1  2.6, respective-
ly. Thus, CHF in the subjects in the present study was associated with
mild or moderate LV systolic dysfunction (EF ranging from
0.29 to 0.54).
Inﬂuence of SNP and ANP on hemodynamics
Effects of SNP and ANP on hemodynamic variables are
summarized in Table 2. Both SNP and ANP decreased LV systolic
pressure (16  3% and 9  2%, respectively, p = 0.06) and LVEDP
(26  7% and 21  4%, respectively, p = 0.63).
Effects of SNP and ANP on contractile and diastolic properties
As shown in Fig. 2a, ANP signiﬁcantly increased peak +dP/dt by
10  3% (p = 0.005), whereas SNP had no inﬂuence (p = 0.22). The
effects of ANP and SNP on diastolic properties are shown in
Table 2. ANP and SNP tended to decrease Tau (9  3% and
7  4%, respectively); however, these changes did not reach
statistical signiﬁcance (p = 0.08 and p = 0.15).NP Control 2 (before ANP) ANP
  10.3* 138.0  11.7 124.3  8.5**
  3.0 14.1  1.3 11.0  1.2
  84 1842  80 2018  88**
  15.8 86.4  15.2 78.8  15.2**
  1.7 63.4  1.9 62.0  1.7
  26.4 169.9  23.5 157.9  31.4
  104* 1841  158 1682  110
  3.4 46.4  2.3 42.4  2.5
tolic pressure; LVEDP, left ventricular end-diastolic pressure; Peak +dP/dt, peak
en content difference; MVO2, myocardial oxygen consumption; Peak dP/dt, peak
.
Fig. 2. Comparison of the response to the administration of SNP or ANP. (a) Comparison of the response to the administration of SNP or ANP on peak positive dP/dt using a
paired t test (#p < 0.05). Two-way repeated measures ANOVA revealed a signiﬁcant effect of ANP compared with SNP (##p < 0.05). (b) Comparison of the Ees response to the
administration of SNP or ANP using a paired t test (#p < 0.05). Two-way repeated measures ANOVA revealed a signiﬁcant effect of ANP compared with SNP (##p < 0.05). (c)
Comparison of the SW/MVO2 response to the administration of SNP or ANP using a paired t test (
#p < 0.05). Two-way repeated measures ANOVA revealed a signiﬁcant effect
of ANP compared with SNP (##p < 0.05). Before, before administration of the drug; During, during administration of the drug; SNP, sodium nitroprusside; ANP, atrial
natriuretic peptide; Peak +dP/dt, peak positive dP/dt; Ees, slope of the LV end-systolic pressure–volume relation; SW, stroke work (J) calculated as the area bound by the
pressure–volume trajectory of 1 beat; MVO2, myocardial oxygen consumption.
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The LV ESPVR was obtained in 8 of 10 patients, because Ees was
not measured in two subjects due to insufﬁcient preload reduction
during the Valsalva maneuver. Therefore, the inﬂuence of SNP
and ANP on mechano-energetic variables was evaluated in eight
subjects.
Representative pressure–volume loops before and after admin-
istration of SNP and ANP are shown in Fig. 3a and b. As shown in
Table 3 and Fig. 2b, ANP increased Ees by 63  24% (p = 0.0087) and
decreased Ea by 11  7%. These alterations resulted in potent
improvement in ventriculoarterial coupling (from 1.47  0.38 to
0.76  0.14), although neither SNP nor ANP had a signiﬁcant effect on
the coronary arteriovenous oxygen content difference or MVO2
(Table 3). ANP improved mechanical-energy transduction (SW/PVA)
by 29  5% (p = 0.0007) and mechanical efﬁciency (SW/MVO2) by
25  9% (p = 0.0073), as shown in Fig. 2c.
SNP had no signiﬁcant effects on the mechano-energetic
variables. SNP did not change Ees, Ea, leading to invariable
ventriculo-arterial coupling. SNP did not change MVO2, SW/PVA,
or SW/MVO2 (Table 3 and Fig. 2c). SNP slightly decreased SW
(16  6%), potential energy (35  6%), and PVA (25  5%).
Effects of SNP and ANP on plasma cGMP levels
The effects of SNP and ANP on plasma cGMP levels in the
coronary sinus are shown in Fig. 4. Regardless of the infusion order
of SNP and ANP, ANP administration signiﬁcantly increased the
plasma cGMP levels, whereas SNP had no effect.Discussion
In the present study, we compared the effects of ANP with those
of SNP on contractility and mechanical efﬁcacy in patients with
CHF associated with mild to moderate LV dysfunction using a
conductance catheter. ANP infusion (0.05 mg/kg/min) and SNP
infusion (0.3 mg/kg/min) similarly decreased LV systolic pressure
and LVEDP; however, these two drugs had opposite effects on
cardiac performance, including LV contractility, mechanical
efﬁciency, and arterial–ventricular coupling. Intravenous infusion
of ANP increased Ees, dP/dt, and SW, and decreased Tau and MVO2
in patients with CHF. In contrast, SNP had no signiﬁcant effects on
these parameters. Thus, this is the ﬁrst report demonstrating that
ANP, but not SNP, improved systolic as well as diastolic properties
in CHF patients. Furthermore, ANP signiﬁcantly increased cardiac
mechanical efﬁciency and ameliorated arterial–ventricular cou-
pling in patients with LV dysfunction.
Several studies have investigated the effects of ANP on cardiac
function. Lainchbury et al. reported that ANP exerts a positive
inotropic effect in normal dogs where tissue cGMP levels would be
expected to be low, and this positive inotropism disappeared in
dogs with HF where tissue cGMP levels would be expected to be
high [8]. On the other hand, Semigran et al. suggested that ANP has
no direct effect on contractility function in the failed heart
[18]. Given the fact that the expression levels of NPR-A are
downregulated in CHF, the effects of ANP on LV contractility might
be dependent upon the cardiac condition [8,19,20], and the
positive inotropic effect of ANP might disappear when the severity
of heart failure exceeds a certain threshold [9]. While the mean
Table 3
Effect of SNP and ANP on mechano-energetic variables.
Control (before SNP) SNP Control 2 (before ANP) ANP
Ees (mmHg/ml/m
2) 1.26  0.21 1.06  0.15 1.30  0.21 1.86  0.32**
Ea (mmHg/ml/m
2) 1.29  0.14 1.27  0.20 1.55  0.20 1.27  0.16
Coupling 1.15  0.13 1.23  0.25 1.47  0.38 0.76  0.14**
SW (J/m2/beat) 0.41  0.05 0.35  0.05 0.42  0.05 0.45  0.05
PVA (J/m2/beat) 0.82  0.11 0.61  0.09* 0.66  0.11 0.71  0.10
SW/PVA (%) 51.5  2.7 57.7  2.9 51.6  4.2 64.6  3.0**
Peak +dP/dt (mmHg/s) 1904  93 1832  84 1842  80 2018  88**
MVO2 (J/beat) 1.98  0.28 1.86  0.29 1.94  0.26 1.80  0.35
SW/MVO2 (%) 40.5  5.8 36.6  5.7 40.5  6.4 50.3  8.0**
CSF (ml/min) 88.4  16.7 83.6  15.8 86.4  15.2 78.8  15.2**
O2 cont diff (vol%) 63.5  2.0 62.1  1.7 63.4  1.9 62.0  1.7
SNP, sodium nitroprusside; ANP, atrial natriuretic peptide; Ees, slope of end-systolic pressure–volume relation; Ea, effective arterial elastance; Coupling, ventriculoarterial
coupling; SW, stroke work; PVA, systolic pressure–volume area; Peak +dP/dt, peak positive dP/dt; MVO2, myocardial oxygen consumption; CSF, coronary sinus blood
ﬂow; O2 cont diff, coronary arteriovenous oxygen content difference.
Values are expressed as mean  SEM.
* p < 0.05 vs control.
** p < 0.05 vs control 2.
Fig. 3. Representative pressure–volume loops. (a) Representative pressure–volume loops following administration of SNP. (b) Representative pressure–volume loops
following administration of ANP. SNP, sodium nitroprusside; ANP, atrial natriuretic peptide; Ees, slope of the LV end-systolic pressure–volume relation.
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Fig. 4. The effects of SNP and ANP on plasma cGMP levels. #p < 0.05 compared with
control, ##p < 0.05 compared with SNP. SNP, sodium nitroprusside; ANP, atrial
natriuretic peptide; cGMP, guanosine 30 ,50-cyclic monophosphate.
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study by Semigran et al. [18]. Baseline differences in the patient
population, especially in terms of residual LV function, might
be one explanation for the discrepancy between our observation
and theirs.
NO donors, like SNP, activate the soluble guanylyl cyclase
system to generate cGMP. Although many experimental studies
have attempted to clarify the inﬂuence of the NO/cGMP-dependent
signaling pathway on cardiac function, there is much controversy.
De Mulder et al. and Prendergast et al. reported that NO donors
enhance systolic function in the b-adrenergic condition in rabbit
hearts or in isolated guinea pig heart, respectively [1,21]. Paolocci
et al. showed that HNO/NO– has positive inotropic actions in
failing hearts of dogs [22]. In contrast, others have proposed that
cGMP does not have a strong inﬂuence on cardiac contractility.
Sandirasegarane and Diamond demonstrated that attenuation of
cardiac contractility by NO donors in vivo occurs by a mechanism
independent of cGMP [23]. Afzal et al. reported that cGMP exerts
positive inotropism in failing rat cardiac ventricle [24]. Thus,
questions remain regarding the actions of exogenous NO on
cardiac function. These different ﬁndings might be due to some
difference in the experimental conditions, such as the state of
cardiac function, bioavailability of exogenous NO donors, etc.
Both ANP and SNP utilize cGMP as an intracellular second
messenger, but the cardiac effects induced by these two agents are
quite different. In the present study, ANP improved cardiac
function and mechanical efﬁciency, whereas SNP had little effect
on cardiac function, although the depressant effects induced by the
two agents were similar. There are several possible explanations
for the difference between ANP and SNP action, e.g. the
compartmentalization of cGMP and indirect effects of ANP, such
as anti-inﬂammatory and anti-oxidative activities. First, a differ-
ence in intracellular localization of cGMP produced by ANP and
SNP should be examined. Castro et al. demonstrated that ANP and
NO donors have different effects on cardiac and vascular smooth
muscle function, and they speculated that these differences are due
to the intracellular compartmentalization of cGMP and the role of
phosphodiesterase (PDE) subtypes, that is, PDE5 controls the
soluble pool and PDE2 exclusively controls the particulate pool
[25,26]. Stasch et al. demonstrated that SNP increases cGMP in
aortic tissue but not in noradrenaline-precontracted isolated
rabbit aorta, on the other hand, ANP causes cGMP production in
the aortic tissue as well as its surrounding bath solution [27]. Theseresults suggest that cGMP produced via soluble guanylyl cyclase by
SNP might not be extruded from the cell, but compartmentalized
into some intracellular spaces. The difference in the intracellular
localization of cGMP induced by SNP and ANP could lead to
different cellular responses. Indeed, administration of ANP induces
marked elevations in the plasma cGMP levels in the coronary sinus,
whereas administration of SNP does not, although these two
reagents had similar vasodilatory effects.
Second, Kiemer et al. demonstrated that ANP attenuated tissue
necrosis factor-a production of lipopolysaccharide-activated
macrophages via cGMP in mouse bone marrow macrophages,
indicating that ANP has potent anti-inﬂammatory and anti-
atherogenic properties [4]. It is possible that the positive inotropic
effects of ANP observed in CHF are mediated by anti-inﬂammatory
and anti-oxidative stress [28].
In the present investigation, we demonstrated that ANP
signiﬁcantly improved mechanical efﬁciency in the heart. Theo-
retically, when Ees equals Ea, the LV can yield to maximum SW
[15,17,29]. Furthermore, Burkhoff and Sagawa showed that when
Ea/Ees is approximately 0.5, the LV adapts to its afterload to make
use of maximum mechanical efﬁciency [30]. In the present study,
we demonstrated that ANP decreased Ea/Ees close to 0.5, whereas
SNP did not (Table 3). Thus, ANP improved the mechano-energetics
in patients with LV dysfunction. Therefore, therapeutic use of
ANP is expected to exert positive inotropism, vasodilatory effects,
and improvement in arterial–ventricular coupling in patients with
LV dysfunction.
Furthermore, cGMP signaling exerts profound effects on the
metabolism pathway in mitochondria of cardiomyocytes [31]. It is
possible that the cGMP-dependent pathway activated by ANP
might directly affect oxidative phosphorylation in the mitochon-
dria. Thus, ANP may decrease MVO2 independently of PVA.
Study limitations
Based on our preliminary study, the doses of SNP and hANP
were set at 0.3 mg/kg/min and 0.05 mg/kg/min, respectively,
because the systemic blood pressure depressant effects were
equivalent at these doses. Ideally, the effects of various doses of
SNP and hANP should be examined using a larger numbers of
patients. In the present study, however, the investigation was
performed in patients with heart failure; therefore, the numbers of
participants and tolerable period for measurement were limited.
There are two methods to reduce the preload for the estimation of
LV function by PV-loop, that is, (1) inferior vena cava (IVC) occlusion
by a balloon catheter and (2) Valsalva maneuver. The IVC occlusion
is a more effective method for reduction of preload compared with
Valsalva maneuver. However, the mechanical reduction of IVC
occlusion is not a physiological method. Furthermore, the IVC
occlusion method is more invasive. Therefore, we chose Valsalva
maneuver in order to alleviate the burden of the subjects. According
to Mizuno’s study [9], it is reported that Ees was 1.9 with IVC
occlusion method. In the present investigation, Ees was normalized
by body surface area, and before the correction, Ees was 2.1. From
these points, our methodology and data are acceptable.
Conclusion
We demonstrated that ANP augmented cardiac contractility,
improved arterial–ventricular coupling and cardiac mechanical
efﬁciency, in patients with mild to moderate LV systolic dysfunc-
tion. These myocardial responses were not observed with SNP
administration. Moreover, ANP improved diastolic function in
these patients as well as SNP. The precise molecular mechanisms
whereby ANP (or cGMP) augments contractility remain to be
T. Ozawa et al. / Journal of Cardiology 66 (2015) 232–238238determined; however, our ﬁnding conﬁrmed that ANP is suitable
for the treatment of patients with CHF.
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